Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.

• Status: Completed
• Trial end date: 2005-11-17
• Target enrollment: 0
• Participant gender: Female

Summary

The aim was to assess the effect of estrogen-progestin therapy (EPT) on serum levels of uric acid (SUA) and its precursors: xanthine (X) and hypoxanthine (HX) and on uric acid (UA) renal excretion in hypertensive postmenopausal women treated with an angiotensin-converting enzyme inhibitor (ACEI) or thiazide diuretic (HCTZ).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Anna Posadzy-Małaczyńska
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Enzyme Inhibitors; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estrogens; Hydrochlorothiazide; Norethindrone; Norethindrone Acetate; Perindopril; Polyestradiol phosphate; Progestins; Uric Acid

Criteria

Inclusion Criteria:

• Treatment-naive postmenopausal women

• Diagnosed hypertension (grade 1 or 2 according to ESH/ESC 2013 guidelines)

Exclusion Criteria:

• breast cancer in a first-degree relative

• hyperplasia diagnosed by endometrial biopsy,

• history of thromboembolic diseases,

• current or history of use of estrogen-progestin therapy or contraceptives

• diabetes,

• kidney failure,

• thyroid disease,

• heart and other chronic diseases (secondary hypertension, atrial fibrillation)